The clinical benefit of hyperthermia in pancreatic cancer: a systematic review
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2017-11-23 / Int J Hyperthermia 2018 11;34(7):969-979IOZK Vortrag von Stefaan Van Gool: IOZK Immuntherapie bei DIPG Ponsgliom, Konferenz der Society for Neuro-Oncology, San Francisco
/0 Kommentare/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZKClinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis
/in Glioblastoma, Hyperthermia, International Publications /von 2017-11-03 / BMJ Open 2017 Nov;7(11):e017387A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-11-01 / Cancer Immunol. Immunother. 2018 02;67(2):285-298
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution